Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor

Molecular Pharmacology

Volumn 82, Issue 5, 2012, Pages 843-859

  Lin, Daniel C H ^a   Guo, Qi ^a   Luo, Jian ^a   Zhang, Jane ^a   Nguyen, Kathy ^a   Chen, Michael ^a   Tran, Thanh ^a   Dransfield, Paul J ^a   Brown, Sean P ^a   Houze, Jonathan ^a   Vimolratana, Marc ^a   Jiao, Xian Yun ^a   Wang, Yingcai ^a   Birdsall, Nigel J M ^b   Swaminath, Gayathri ^a  

^a AMGEN INC   (United States)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AM 1638; AM 8182; AMG 837; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR 40; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC SITE; ANIMALS; ARGININE; BIPHENYL COMPOUNDS; CELL LINE; DOCOSAHEXAENOIC ACIDS; DRUG PARTIAL AGONISM; DRUG SYNERGISM; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MUTATION; PHENYLPROPIONATES; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867306794     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079640     Document Type: Article

References (51)

1. Allderdice PW, Miller OJ, Miller DA, Warburton D, Pearson PL, Klein G, and Harris H (1973) Chromosome analysis of two related heteroploid mouse cell lines by quinacrine fluorescence. J Cell Sci 12:263-274.
2. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, Gesta S, Ronald Kahn C, Smith RD, Jetton TL, Metz TO, et al. (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58:2607-2615.
3. An S, Bleu T, Zheng Y, and Goetzl EJ (1998) Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. MolPharmacol 54:881-888. (Pubitemid 28523180)
4. Araki T, Hirayama M, Hiroi S, and Kaku K (2012) GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14:271-278.
5. Bharate SB, Nemmani KV, and Vishwakarma RA (2009) Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin TherPat 19:237-264.
6. Bharate SB, Rodge A, Joshi RK, Kaur J, Srinivasan S, Kumar SS, Kulkarni-Almeida A, Balachandran S, Balakrishnan A, and Vishwakarma RA (2008) Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg MedChem Lett 18:6357-6361.
7. Birdsall NJ and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5:523-543. (Pubitemid 40754167)
8. Black JW and Leff P (1983) Operational models of pharmacological agonism.Proc RSoc Lond B Biol Sci 220:141-162. (Pubitemid 14217337)
9. Bridges TM and Lindsley CW (2008) G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 3:530-541.
10. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, McCoy DC, Kenakin TP, Andrews JL, Ammala C, et al. (2006) Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148:619-628. (Pubitemid 43993052)
11. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J BiolChem 278:11303-11311. (Pubitemid 36792687)
12. Brown SP, Cao Q, Dransfield PJ, Du X, Fu Z, Houze J, Jiao XY, Kim YJ, Kohn TJ, Lai S, et al. (2011), inventors; Amgen Inc., assignee. Substituted biphenyl GPR40 modulators. U.S. Patent 8,030,354. 2011 Oct 4.
13. Christiansen E, Urban C, Grundmann M, Due-Hansen ME, Hagesaether E, Schmidt J, Pardo L, Ullrich S, Kostenis E, Kassack M, et al. (2011) Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. J Med Chem 54:6691-6703.
14. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov8:41-54.
15. Costanzi S, Neumann S, and Gershengorn MC (2008) Seven transmembranespanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem 283:16269-16273.
16. Doshi LS, Brahma MK, Sayyed SG, Dixit AV, Chandak PG, Pamidiboina V, Motiwala HF, Sharma SD, and Nemmani KV (2009) Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Metab Clin Exp 58:333-343.
17. Garrido DM, Corbett DF, Dwornik KA, Goetz AS, Littleton TR, McKeown SC, Mills WY, Smalley TL Jr, Briscoe CP, and Peat AJ (2006) Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett 16:1840-1845. (Pubitemid 43267362)
18. Hara T, Hirasawa A, Sun Q, Sadakane K, Itsubo C, Iga T, Adachi T, Koshimizu TA, Hashimoto T, Asakawa Y, et al. (2009) Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol 380:247-255.
19. Herrington J, Zhou YP, Bugianesi RM, Dulski PM, Feng Y, Warren VA, Smith MM, Kohler MG, Garsky VM, Sanchez M, et al. (2006) Blockers of the delayed-rectifier potassium current in pancreatic beta-cells enhance glucose-dependent insulin secretion. Diabetes 55:1034-1042. (Pubitemid 44100179)
20. Hu H, He LY, Gong Z, Li N, Lu YN, Zhai QW, Liu H, Jiang HL, Zhu WL, and Wang HY (2010) A novel class of antagonists for the FFAs receptor GPR40. BiochemBiophys Res Commun 390:557-563.
21. Hudson BD, Smith NJ, and Milligan G (2011) Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. Adv. Pharmacol 62:175-218.
22. Humphries PS, Benbow JW, Bonin PD, Boyer D, Doran SD, Frisbie RK, Piotrowski DW, Balan G, Bechle BM, Conn EL, et al. (2009) Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorg Med Chem Lett 19:2400-2403.
23. Itoh Y and Hinuma S (2005) GPR40, a free fatty acid receptor on pancreatic β cells, regulates insulin secretion. Hepatol Res 33:171-173. (Pubitemid 41799798)
24. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 422:173-176. (Pubitemid 36362750)
25. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, and Poitout V (2008) The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57:2432-2437.
26. Lan H, Hoos LM, Liu L, Tetzloff G, Hu W, Abbondanzo SJ, Vassileva G, Gustafson EL, Hedrick JA, and Davis HR (2008) Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57:2999-3006.
27. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, Lin DC, and Poitout V (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56:1087-1094. (Pubitemid 46525064)
28. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
29. Lazareno S, Gharagozloo P, Kuonen D, Popham A, and Birdsall NJ (1998) Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol 53:573-589. (Pubitemid 28162882)
30. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci28:382-389. (Pubitemid 47087967)
31. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, Tran T, Lopez E, Lu JY, Li XN, et al. (2011) AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 6:e27270.
32. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51. (Pubitemid 46277033)
33. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, Tanaka H, Nakata M, Yano T, Shimakawa K, Taketomi S, et al. (2009) Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerancein normal and diabetic mice. Diabetes 58:1067-1076.
34. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, and Leifke E (2012) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52:1007-1016.
35. Sasaki S, Kitamura S, Negoro N, Suzuki M, Tsujihata Y, Suzuki N, Santou T, Kanzaki N, Harada M, Tanaka Y, et al. (2011) Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J Med Chem 54:1365-1378.
36. Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, and O'Dowd BF (1997) A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun239:543-547. (Pubitemid 27489000)
37. Smith NJ, Stoddart LA, Devine NM, Jenkins L, and Milligan G (2009) The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J BiolChem 284:17527-17539.
38. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, and Edlund H (2005) The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 1:245-258. (Pubitemid 43960613)
39. 35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 71:994-1005.
40. Stoddart LA, Smith NJ, and Milligan G (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60:405-417.
41. Sum CS, Tikhonova IG, Costanzi S, and Gershengorn MC (2009) Two arginineglutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem 284: 3529-3536.
42. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S, and Gershengorn MC (2007) Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282:29248-29255. (Pubitemid 350043382)
43. Swaminath G (2008) Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch Pharm (Weinheim) 341:753-761.
44. 2+. Mol Pharmacol 61:65-72.
45. Tahara A, Matsuyama-Yokono A, and Shibasaki M (2011) Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol 655:108-116.
46. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro G, Meinke P, Mosley R, et al. (2008) Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57:2211-2219.
47. Tikhonova IG, Sum CS, Neumann S, Thomas CJ, Raaka BM, Costanzi S, and Gershengorn MC (2007) Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J MedChem 50:2981-2989. (Pubitemid 47001241)
48. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, and Takeuchi K (2011) TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339:228-237.
49. Walker SD, Borths CJ, DiVirgilio E, Huang L, Liu P, Morrison H, Sugi K, Tanaka M, Woo JCS, and Faul MM (2011) Development of a scalable synthesis of a GPR40 agonist. Org Process Res Dev 15:570-580.
50. Walsh SP, Severino A, Zhou C, He J, Liang GB, Tan CP, Cao J, Eiermann GJ, Xu L, Salituro G, et al. (2011) 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists. Bioorg Med Chem Lett 21:3390-3394.
51. Zhou C, Tang C, Chang E, Ge M, Lin S, Cline E, Tan CP, Feng Y, Zhou YP, Eiermann GJ, et al. (2010) Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists. Bioorg Med Chem Lett 20:1298-1301.